MAPTMicrotubule-Associated Protein Tau
MAPTMissed Approach Point (aviation)
MAPTMagnetically Actuated Peel Test
MAPTMulti-Attribute Prioritisation Tool
MAPTMaintenance Activation Planning Team
MAPTMassachusetts Association for Pupil Transportation
MAPTMulti-Agency Project Team (UK)
MAPTMulti-attribute Arthritis Prioritisation Tool (Australia)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
For an MAPT, the Hill exemption will be available if the document is structured as a grantor trust under IRC section 671.
In candidate gene studies, single-nucleotide polymorphisms (SNPs) in SCARB2 (rs6812193) and MAPT (rs12185268) were significantly associated with RBD.[15] RBD patients who carried the USP25 SNP rs2823357 converted to a-synucleinopathies faster than who did not.[15] Patients with PD who carried GBA mutation had an odds ratio ( OR ) of 6.24 for RBD and an OR of 3.13 for probable RBD.[16] Carriers of the PINK1 SNP rs45478900 among BRD patients have a higher risk for conversion to PD ( OR : 2.92) than noncarriers.[17] However, it seemed that the APOE*?4 allele was not associated with both the risk of RBD occurrence and its conversion to any a-synucleinopathy.[18]
We examined whether variations in apolipoprotein E (ApoE) and microtubule-associated protein tau (MAPT) genotypes are associated with cognitive decline in PD.
According to the protein quantitative verification result of Western blot, we found that the expressions of Prkc and Mapt are consistent with the previous iTRAQ analysis result.
(2,7,8) Created by an inversion with several superimposed deletions, dysfunction is caused by hyperphosphorylation and aggregation of the microtubule-association protein tau (MAPT) in white matter and depends upon anatomic area, cell type and specific isoform of tau deposits.
MAPT was responsible for analysis, discussion and drafting of the article.
The Multidomain Alzheimer's Preventive Trial (MAPT) was designed to assess the efficacy of supplementation with omega-3s on the change in cognitive functions in subjects 70 years and older with subjective memory complaints.
The Multidomain Alzheimer Preventive Trial (MAPT) comprised 1,680 people who had reported subjective memory complaints to their primary care physician.
In the present study, we focus on the microtubule-associated protein tau (MAPT).
(10) Furthermore, deposition of proteins such as beta-amyloid and phosphorylated microtubule-associated protein tau (MAPT) may contribute to muscle injury.
The validation process presented by Sireci (2012) to support the use of the Massachusetts Adult Proficiency Tests (MAPT), clearly illustrates, as discussed below, the complementarity of the two sources.